Ovid Therapeutics and Graviton Bioscience Announce Topline Data From a Phase 1 Clinical Trial Studying Ov888/Gv101 Capsule, a Potential First-in-Class Therapy for Cerebral Cavernous Malformations
ovid therapeutics和Graviton生物科技宣佈了從一項Ⅰ期臨床試驗中得出的關鍵數據，該試驗研究了Ov888 / Gv101膠囊，這是潛在的第一類腦室畸形療法。